|
|
|
| |
| Company Profile |
| |
|
CytRx Corporation, a biopharmaceutical company, engages in the development and commercialization of human therapeutics, primarily in the area of ribonucleic acid interference and small molecules for the human health care market. The company, through its subsidiary, CytRx Laboratories, Inc., develops orally active small molecule based drugs to prevent, treat, and cure obesity and type II diabetes. It also focuses on research and development activities of FLOCOR, an intravenous agent for acute vaso-occlusive disorders and related acute care applications; and TranzFect, a DNA delivery technology, which have applications in DNA vaccines and gene therapy. In addition, the company has research activities in the areas of infectious disease, drug delivery, and animal feed additives. CytRx has strategic alliance with the University of Massachusetts Medical School to develop compounds in the areas of amyotrophic lateral sclerosis, obesity, type II diabetes, and cytomegalovirus using RNAi technology. The company was incorporated in 1985 and is headquartered in Los Angeles, California.
|
CYTRX CP Related |
|
CYTR: Technical Analysis for CYTRX CP - Yahoo! Finance Get the chart for CYTRX CP (CYTR) and see various technical analysis indicators including MACD, MFI, ROC, RSI, Slow Stoch, Fast Stoch and overlays such as bollinger ...
|
|
CYTR: Summary for CYTRX CP - Yahoo!7 Finance - Share Prices, Charts ... CYTRX CP - CYTR - Summary, Chart, Share Price and further stock info ... CYTRX CP (NCM:CYTR) Delayed quote data. Last Trade: 0.5197 USD. Trade Time: 7:59AM AEST ...
|
|
CYTR: Summary for CYTRX CP - Yahoo! Singapore Finance - Share Prices ... CYTRX CP - CYTR - Summary, Chart, Share Price and further stock info ... CytRx Corporation's 45% Owned Affiliate RXi Pharmaceuticals Obtains an Exclusive ...
|
|
